Overview
Recognizing the Substantial Burden of Alopecia in Pediatric Patients and Building Multidisciplinary Capacity and Competence to Address Unmet Needs
Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.
Start ActivityCME/CE is no longer available for this activity
Hair loss can have a profound psychological impact, especially on adolescents who may face social stigma or have self-esteem issues. Accurate diagnosis and appropriate management in this patient population can improve not only physical symptoms but also mental well-being.
If you’re a clinician who treats alopecia areata (AA) in pediatric patients, take your skills to the next level by accessing ACHL’s AdaptED® platform, which offers a tailored learning experience for busy clinicians, addressing your specific goals and knowledge gaps while providing practical insights and strategies for immediate application in practice. Whether you are an early career clinician or an advanced provider, stay up to date on the latest evidence and evolving practices on diagnosing and treating AA in pediatric patients. Enhance patient care by accessing the ACHL AdaptED® platform today.
Not sure if adaptive learning is right for you? Hear from our expert faculty about the advantages of the ACHL AdaptED® learning experience:
Hear from our expert faculty about the advantages of the ACHL AdaptED® learning experience:
This activity is intended for pediatric dermatologists, dermatologists, pediatricians, advanced practice practitioners in dermatology practice, primary care providers and other clinicians who manage pediatric alopecia.
Alopecia areata (AA) is a persistent immune-related condition that primarily affects hair follicles and leads to hair loss. It typically manifests as isolated, hairless areas on the scalp, though it can also appear on other regions with hair, including the eyebrows, eyelashes, beard, and limbs. AA affects roughly 6.7 million individuals in the United States and can strike individuals of all ages, genders, races, and ethnic backgrounds. This surprisingly common condition often imposes a significant burden that extends beyond hair loss, negatively affecting a patient’s self-esteem and their ability to feel accepted in both personal and social spheres within society, leading to reduced quality of life and psychological consequences such as anxiety and depression. Due to the historical absence of approved therapies in adolescent patients, addressing AA in this population has been difficult. However, the AA treatment paradigm in the pediatric setting is rapidly shifting thanks to the emergence of newly approved therapies. Although these agents have ushered in a new era of hope for adolescent patients affected by AA, busy clinicians need to enhance their knowledge and competence in the diagnosis, assessment, and treatment of AA to optimize clinical practices and incorporate novel therapies within evolving management strategies
Upon completion of this activity, learners will be able to:
• Summarize the disease burden experienced by adolescents with alopecia areata (AA), including both psychosocial and medical comorbidities.• Discuss appropriate strategies for diagnosing AA and assessing severity of the disease.
• Evaluate clinical safety and efficacy data pertaining to new and emerging therapies for AA treatment in adolescent patients.
• Incorporate oral Janus kinase (JAK) inhibitors into evolving AA treatment plans for adolescent patients.
Provided by the Academy for Continued Healthcare Learning (ACHL) and Purdue University College of Pharmacy Office of Continuing Education and Professional Development.
Supported by an educational grant from Pfizer, Inc.
Carolyn Goh, MD (Faculty)
Associate Clinical Professor in Dermatology
UCLA David Geffen School of Medicine
University of California
Los Angeles, CA
Associate Clinical Professor in Dermatology
UCLA David Geffen School of Medicine
University of California
Los Angeles, CA
Lacey L. Kruse, MD, FAAD (Faculty)
Associate Professor of Pediatrics and Dermatology
Northwestern University Feinberg School of Medicine
Program Director, Pediatric Dermatology Fellowship
Ann & Robert H. Lurie Children’s Hospital of Chicago
Chicago, IL
Diane Hountz, DNP, MS, ANP, RN, CNE (Nurse Planner)
Clinical Associate Professor, School of Nursing
Director of Professional Development, Lead Nurse Planner
Purdue University
West Lafayette, IN
Purdue University College of Pharmacy and the Academy for Continued Healthcare Learning (ACHL) require that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with all ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
Carolyn Goh, MD (Faculty)
Consulting Agreements: Radicle Sciences, Sagimet Biosciences
Advisory Board: Pelage Pharmaceuticals
Contributor: BMJ BestPractices
Speakers' Bureau: Pfizer, Inc.
Interleukin-15 (IL-15) inhibitors, NKG2D inhibitors, topical corticosteroids, minoxidil, topical anthralin, topical calcineurin inhibitors (eg, tacrolimus), tofacitinib, ruxolitinib, oral corticosteroids, intralesional corticosteroids, diphenylcyclopropenone, squaric acid dibutyl ester, platelet-rich plasma (PRP), cryotherapy, excimer laser therapy, mycophenolate mofetil, cyclosporine, sulfasalazine, methotrexate, dapsone, ustekinumab, IL-17A inhibitors, apremilast, abrocitinib, brepocitinib, delgocitinib, and upadacitinib are not approved for the treatment of alopecia areata. Baricitinib is not approved for the treatment of alopecia areata in patients <18 years of age.
The following financial relationships have been provided:
Carolyn Goh, MD (Faculty)
Consulting Agreements: Radicle Sciences, Sagimet Biosciences
Advisory Board: Pelage Pharmaceuticals
Contributor: BMJ BestPractices
Speakers' Bureau: Pfizer, Inc.
Lacey Kruse (Faculty)
Sources of Funding for Research: Leo Pharma, Sanofi
Diane Hountz, DNP, MS, ANP, RN, CNE (Nurse Planner)
No financial relationships to disclose
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use:
Purdue University College of Pharmacy, ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. Purdue University College of Pharmacy and ACHL require the speaker to disclose that a product is not labeled for the use under discussion.
To receive credit, learners are required to view the online activity and complete the posttest and evaluation. There is no fee to participate in the activity or for the generation of the certificate.
Purdue University College of Pharmacy is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians
Purdue University College of Pharmacy designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Purdue University Continuing Nursing Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.This program is approved for 2.0 contact hours.
